Novsoste BetaCath Shows Zero Rate Of Late-Stent Thrombosis START Trial
This article was originally published in The Gray Sheet
Executive Summary
Novoste Corp. appears poised for a smooth path to FDA approval for the BetaCath beta radiation system, given the 0% incidence of late-stent thrombosis in treating patients for in-stent restenosis.
You may also be interested in...
Novoste Building Sales Force, Preparing For Sept. 11 Beta-Cath Panel Review
Novoste will ramp up its sales force this fall in preparation for the U.S. launch of the Beta-Cath beta radiation catheter system, which will take place immediately following FDA approval.
Novoste Building Sales Force, Preparing For Sept. 11 Beta-Cath Panel Review
Novoste will ramp up its sales force this fall in preparation for the U.S. launch of the Beta-Cath beta radiation catheter system, which will take place immediately following FDA approval.
Implant Sciences System Could Address Gamma Radiation Safety Concerns
Implant Sciences feels its "soft" gamma ray-emitting system for the prevention of restenosis following coronary angioplasty is capable of overcoming hospital personnel safety concerns associated with similar brachytherapy systems.